The latest update is out from Kintara Therapeutics ( (KTRA) ).
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kintara Therapeutics has announced its fiscal 2024 financial results, revealing a net loss decrease compared to the previous year, largely due to reduced research and development expenses. The company, which specializes in novel cancer therapies, has also provided a corporate update detailing its merger with TuHURA Biosciences and the progress of their REM-001 study for cutaneous metastatic breast cancer, funded in part by a National Institutes of Health grant. The merger is set to enhance Kintara’s portfolio with TuHURA’s immune-oncology developments and is expected to close mid-October, pending final conditions.
For an in-depth examination of KTRA stock, go to TipRanks’ Stock Analysis page.
